Literature DB >> 3129208

Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep. Evidence for the role of reactive oxygen metabolites following nonimmunological complement activation.

D R Morel1, E Lowenstein, T Nguyenduy, D R Robinson, J E Repine, D E Chenoweth, W M Zapol.   

Abstract

When protamine (2 mg/kg) was injected intravenously into awake sheep 5 minutes after infusing heparin (200 units/kg), there was transient diffuse pulmonary vasoconstriction with mean pulmonary arterial pressure increasing from 18.0 +/- 0.7 to 43.8 +/- 2.7 mm Hg at 1 minute (x +/- SEM; n = 10). In addition, there was profound leukopenia (36.9 +/- 7.7% of baseline values at 2 minutes) with transpulmonary leukocyte sequestration and transiently elevated plasma concentrations of C3a (from 420 +/- 146 to 1,599 +/- 249 ng/ml; n = 3, p less than 0.01) and thromboxane B2 (from 0.30 +/- 0.05 to 6.3 +/- 2.8 ng/ml; n = 10, p less than 0.0001), without significant increases of plasma 6-keto-prostaglandin F1 alpha, prostaglandin F2 alpha, leukotrienes, or histamine. Intravenous injection of protamine alone produced no hemodynamic effects and did not increase plasma levels of vasoconstrictor eicosanoids. Intravenous pretreatment with either a cyclooxygenase inhibitor or a hydrogen peroxide scavenger (dimethylthiourea) blocked both the increases of thromboxane levels and the pulmonary vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129208     DOI: 10.1161/01.res.62.5.905

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  9 in total

1.  Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.

Authors:  L C Chang; J F Liang; H F Lee; L M Lee; V C Yang
Journal:  AAPS PharmSci       Date:  2001

2.  The beneficial effects of aminophylline administration on heparin reversal with protamine.

Authors:  S F Katircioglu; D S Küçükaksu; M Bozdayi; K Dalva; B Mavitaş; Y Zorlutuna; O Taşdemir; K Bayazit
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

3.  Thiourea and dimethylthiourea decrease human neutrophil bactericidal function in vitro.

Authors:  J H Jackson; E M Berger; J E Repine
Journal:  Inflammation       Date:  1988-10       Impact factor: 4.092

Review 4.  Allergy to protamine.

Authors:  M E Weiss; N F Adkinson
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

5.  Prevention of the pulmonary vasoconstrictor effects of HBOC-201 in awake lambs by continuously breathing nitric oxide.

Authors:  Binglan Yu; Gian Paolo Volpato; Keqin Chang; Kenneth D Bloch; Warren M Zapol
Journal:  Anesthesiology       Date:  2009-01       Impact factor: 7.892

6.  Heparin-enhanced plasma phospholipase A2 activity and prostacyclin synthesis in patients undergoing cardiac surgery.

Authors:  H Nakamura; D K Kim; D M Philbin; M B Peterson; F Debros; G Koski; J V Bonventre
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

7.  The Toxicokinetic Profile of Dex40-GTMAC3-a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin.

Authors:  Emilia Sokolowska; Bartlomiej Kalaska; Kamil Kaminski; Alicja Lewandowska; Agnieszka Blazejczyk; Joanna Wietrzyk; Irena Kasacka; Krzysztof Szczubialka; Dariusz Pawlak; Maria Nowakowska; Andrzej Mogielnicki
Journal:  Front Pharmacol       Date:  2016-03-17       Impact factor: 5.810

8.  Dimethylthiourea inhibition of B16 melanoma growth and induction of phenotypic alterations; relationship to ATP levels.

Authors:  A Fux; Y Sidi; G Kessler-Icekson; L Wasserman; A Novogrodsky; J Nordenberg
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

9.  Cardiovascular and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent Models.

Authors:  Joanna Miklosz; Bartlomiej Kalaska; Piotr Podlasz; Małgorzata Chmielewska-Krzesińska; Miłosz Zajączkowski; Adam Kosiński; Dariusz Pawlak; Andrzej Mogielnicki
Journal:  Pharmaceutics       Date:  2021-03-09       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.